AR036199A1 - Metodos y composiciones para el tratamiento de enfermedades oftalmicas - Google Patents

Metodos y composiciones para el tratamiento de enfermedades oftalmicas

Info

Publication number
AR036199A1
AR036199A1 ARP020102892A ARP020102892A AR036199A1 AR 036199 A1 AR036199 A1 AR 036199A1 AR P020102892 A ARP020102892 A AR P020102892A AR P020102892 A ARP020102892 A AR P020102892A AR 036199 A1 AR036199 A1 AR 036199A1
Authority
AR
Argentina
Prior art keywords
compositions
treatment
methods
diseases
ophthalm
Prior art date
Application number
ARP020102892A
Other languages
English (en)
Inventor
Bender Hans Markus Dr
Haunschild Jutta Dr
Lang Ulrich Dr
Wiesner Matthias Dr
Friedlander Martin Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR036199A1 publication Critical patent/AR036199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

Métodos y composiciones para la profilaxis y/o tratamiento de enfermedades oftálmicas usando antagonistas de los receptores de integrina alfavbeta3 y/o alfavbeta5. Las composiciones pueden ser nanopartículas y se administran en el ojo por inyección en el cuerpo vítreo.
ARP020102892A 2001-08-01 2002-07-31 Metodos y composiciones para el tratamiento de enfermedades oftalmicas AR036199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01

Publications (1)

Publication Number Publication Date
AR036199A1 true AR036199A1 (es) 2004-08-18

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102892A AR036199A1 (es) 2001-08-01 2002-07-31 Metodos y composiciones para el tratamiento de enfermedades oftalmicas

Country Status (20)

Country Link
US (2) US20040198644A1 (es)
EP (1) EP1411926B1 (es)
JP (1) JP2005504757A (es)
KR (1) KR20040028966A (es)
CN (1) CN1536998A (es)
AR (1) AR036199A1 (es)
AT (1) ATE296628T1 (es)
AU (1) AU2002319282B2 (es)
BR (1) BR0211604A (es)
CA (1) CA2456076C (es)
DE (1) DE60204466T2 (es)
DK (1) DK1411926T3 (es)
ES (1) ES2243744T3 (es)
HU (1) HUP0401605A3 (es)
MX (1) MXPA04000839A (es)
PL (1) PL207175B1 (es)
PT (1) PT1411926E (es)
RU (1) RU2311177C2 (es)
WO (1) WO2003013511A1 (es)
ZA (1) ZA200401598B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
CN102427816A (zh) 2009-03-30 2012-04-25 宇部兴产株式会社 用于治疗或预防眼病的药物组合物
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
EA032552B1 (ru) 2012-03-16 2019-06-28 Дзе Джонс Хопкинс Юниверсити Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
EA030318B1 (ru) 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
CA3007198A1 (en) * 2015-12-04 2017-06-08 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
AU2017359027A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903921B2 (ja) * 1995-08-14 2012-03-28 ザ スクリプス リサーチ インスティチュート αＶβ５仲介血管形成の阻止に有効な方法及び組成物
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP2000516201A (ja) * 1996-05-31 2000-12-05 ザ スクリップス リサーチ インスティテュート 血管形成阻害方法及び血管形成阻害に有用な組成物
PL330241A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods of and compositions useful in inhibiting angiogenesis
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
EP1061916A2 (en) * 1998-03-13 2000-12-27 Centaur Pharmaceuticals, Inc. Use os nitrone compounds for the inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
US20060287225A1 (en) 2006-12-21
CA2456076C (en) 2011-08-23
DE60204466T2 (de) 2006-04-27
MXPA04000839A (es) 2004-05-14
US20040198644A1 (en) 2004-10-07
PT1411926E (pt) 2005-10-31
ATE296628T1 (de) 2005-06-15
KR20040028966A (ko) 2004-04-03
CA2456076A1 (en) 2003-02-20
US7645736B2 (en) 2010-01-12
DE60204466D1 (de) 2005-07-07
ES2243744T3 (es) 2005-12-01
HUP0401605A3 (en) 2012-09-28
PL367959A1 (en) 2005-03-07
RU2311177C2 (ru) 2007-11-27
RU2004106527A (ru) 2005-07-10
BR0211604A (pt) 2004-08-24
CN1536998A (zh) 2004-10-13
EP1411926A1 (en) 2004-04-28
PL207175B1 (pl) 2010-11-30
AU2002319282B2 (en) 2007-06-28
JP2005504757A (ja) 2005-02-17
HUP0401605A2 (hu) 2004-11-29
EP1411926B1 (en) 2005-06-01
DK1411926T3 (da) 2005-08-29
ZA200401598B (en) 2004-11-17
WO2003013511A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
LTPA2016034I1 (lt) Brutono tirozinkinazės inhibitoriai
NO20052988D0 (no) Farmakologisk vitreolyse.
AR048646A1 (es) Implante intraocular o intravitreo biodegradable que comprende un inhibidor de tirosina quinasa y un polimero biodegradable, metodo para producirlo y medicamento correspondiente
AR034619A1 (es) Formulaciones de olopatadine para administracion topica
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
DK1474109T3 (da) Anvendelse af syntetiske uorganiske nanopartikler som bærere af ophthalmiske lægemidler
TW200505402A (en) Ophthalmic drug delivery device
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
BRPI0507609A (pt) combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
HUP0203844A2 (hu) Növekedési hormon kibocsátó tulajdonságú vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása
DOP2003000747A (es) Composiciones oftalmicas para el tratamiento de la hipertension ocular
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
CY1121044T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια οφθαλμικων διαταραχων
ECSP045210A (es) 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco
AR018824A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el control de la presion intraocular y en el tratamiento del glaucoma
AR018825A1 (es) Antagonistas del receptor de bradiquinina no peptidica para uso en el tratamiento de trastornos y enfermedades oftalmicas
ATE344054T1 (de) Behandlung von okularen neovaskularen erkrankungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal